{"Abbreviation":"5-HTP","Aliases":["5-hydroxytryptophan","5-Hydroxy-DL-tryptophan","DL-5-Hydroxytryptophan","114-03-4","5-HTP","DL-Hydroxytryptophan","(+-)-5-Hydroxytryptophan","DL-5-HTP","5-Hydroxytryptophan DL-form","5-hydroxy tryptophan"],"CAS":"56-69-9","ChEBI":"CHEBI:28171","ChEMBL":"CHEMBL162789","ChemicalClasses":["tryptamine"],"Chirality":"racemic","Color/Form":"Minute rods or needles from ethanol","Dosing Info":[],"Drug Warnings":"Other reported side effects, include nausea, diarrhea, loss of appetite, vomiting and difficult breathing. Neurological side effects, including dilation of the pupils, abnormally sensitive reflexes, loss of muscle coordination and blurring of vision, have been reported in those taking large doses of 5-HTP. Cardiac dysrhythmias have also been reported.","DrugClasses":[],"EINECS":"200-284-8","European Community (EC) Number":"200-284-8","HeavyAtomCount":16,"IUPACName":"2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid","InChI":"InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)","InChIKey":"LDCYZAJDBXYCGN-UHFFFAOYSA-N","MeSH Pharmacological Classification":"A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)","Melting Point":"298-300 °C (decomposes)","MolecularFormula":"C\u003csub\u003e11\u003c/sub\u003eH\u003csub\u003e12\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"220.22 g/mol","Opticalactivity":"( + / - )","PrevSalts":[],"PubChemId":144,"Record Description":["5-hydroxytryptophan is a tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5. It has a role as a human metabolite and a neurotransmitter.","5-Hydroxytryptophan has been reported in Panaeolus semiovatus and Solanum lycopersicum with data available.","5-Hydroxytryptophan, DL- is a racemic mixture of 5-hydroxytryptophan (5-HTP), a precursor to the neurotransmitter serotonin with anti-depressant, analgesic and appetite-suppressant activities. DL-5-HTP is decarboxylated to serotonin by aromatic-L-amino-acid decarboxylase, and results in increased serotonin levels within the brain. Mediated through serotonin receptors, elevated levels of serotonin causes increased serotonin neurotransmissions, hence leading to release of depression, pain and appetite.","5-Hydroxy-L-tryptophan is an aromatic amino acid naturally produced by the body from the essential amino acid l-tryptophan. 5-Hydroxy-L-tryptophan is the immediate precursor of the neurotransmitter serotonin. The conversion to serotonin is catalyzed by the enzyme aromatic l-amino acid decarboxylase (EC 4.1.1.28, AADC1 also known as dopa decarboxylase), an essential enzyme in the metabolism of the monoamine neurotransmitters. An accumulation of 5-Hydroxy-L-tryptophan in cerebrospinal fluid occurs in Aromatic l-amino acid decarboxylase deficiency (OMIM 608643), accompanied by an increased excretion in the urine of the patients, which are indicative of the disorder but not specific 5-Hydroxy-L-tryptophan is also increased in other disorders such as in Parkinson's patients with severe postural instability and gait disorders. Confirmation of the diagnosis AADC deficiency is then required by enzyme activity measurement or genetic analysis. The amount of endogenous 5-Hydroxy-L-tryptophan available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase (EC 1.14.16.4), indoleamine 2,3-dioxygenase (EC 1.13.11.52), and tryptophan 2,3-dioxygenase. (EC 1.13.11.11, TDO). 5-Hydroxy-L-tryptophan has been used clinically for over 30 years. In addition to depression, the therapeutic administration of 5-Hydroxy-L-tryptophan has been shown to be effective in treating a wide variety of conditions, including fibromyalgia, insomnia, binge eating associated with obesity, cerebellar ataxia, and chronic headaches. 5-Hydroxy-L-tryptophan easily crosses the blood-brain barrier and effectively increases central nervous system (CNS) synthesis of serotonin. Supplementation with 5-Hydroxy-L-tryptophan is hypothesized to normalize serotonin synthesis, which is putatively related to its antidepressant properties.  (A3384, A3385, A3386).","The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.","See also: Oxitriptan (annotation moved to).","5-hydroxytryptophan is a tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5. It has a role as a human metabolite and a neurotransmitter."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/5-Hydroxytryptophan","Name":"Oxitriptan","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q27103541","Name":"Oxitriptan","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/144","Name":"Oxitriptan","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL162789","Name":"Oxitriptan","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28171","Name":"Oxitriptan","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=56-69-9","Name":"Oxitriptan","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C01017","Name":"Oxitriptan","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/9181P3OI6N","Name":"Oxitriptan","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID50859863","Name":"Oxitriptan","Sub":false}]}],"SMILES":"C1=CC2=C(C=C1O)C(=CN2)CC(C(=O)O)N","Solubility":"Solubilities: 2.5 g/100 mL in 50% boiling alcohol; 5.5 g/100 mL in water at 100 °C","Stability/Shelf Life":"AQ SOLN ARE STABLE @ LOW PH /DL-FORM/","StereoisomerRacemic":"(RS)-Oxitriptan","StoreUNII":["9181P3OI6N"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="62.782mm" version="1.2" viewBox="0 0 105.306 62.782" width="105.306mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="63.0" stroke="none" width="106.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="1.635" x2="6.352" y1="28.902" y2="43.402"/>
                        
                <line x1="4.389" x2="8.235" y1="29.487" y2="41.31"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="6.352" x2="21.266" y1="43.402" y2="46.577"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="21.266" x2="31.463" y1="46.577" y2="35.252"/>
                        
                <line x1="20.396" x2="28.709" y1="43.899" y2="34.667"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="31.463" x2="26.747" y1="35.252" y2="20.751"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="26.747" x2="11.833" y1="20.751" y2="17.576"/>
                        
                <line x1="24.863" x2="12.702" y1="22.843" y2="20.254"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="1.635" x2="11.833" y1="28.902" y2="17.576"/>
                  
            <line class="bond" id="mol1bnd7" x1="11.833" x2="8.364" y1="17.576" y2="6.897"/>
                  
            <line class="bond" id="mol1bnd8" x1="31.463" x2="45.388" y1="35.252" y2="41.5"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="43.806" x2="45.388" y1="56.619" y2="41.5"/>
                        
                <line x1="41.565" x2="42.779" y1="54.601" y2="43.002"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="43.806" x2="32.246" y1="56.619" y2="59.07"/>
                  
            <line class="bond" id="mol1bnd11" x1="21.266" x2="26.808" y1="46.577" y2="56.112"/>
                  
            <line class="bond" id="mol1bnd12" x1="45.388" x2="58.595" y1="41.5" y2="33.896"/>
                  
            <line class="bond" id="mol1bnd13" x1="58.595" x2="71.784" y1="33.896" y2="41.533"/>
                  
            <line class="bond" id="mol1bnd14" x1="71.784" x2="84.992" y1="41.533" y2="33.929"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="83.772" x2="83.786" y1="34.631" y2="22.609"/>
                        
                <line x1="86.21" x2="86.225" y1="34.634" y2="22.612"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="83.786" x2="83.779" y1="22.609" y2="28.62"/>
                <line class="hi" stroke="#FF0D0D" x1="86.225" x2="86.2175" y1="22.612" y2="28.622999999999998"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="84.992" x2="94.899" y1="33.929" y2="39.665"/>
                  
            <line class="bond" id="mol1bnd17" x1="71.784" x2="71.77" y1="41.533" y2="52.923"/>
                  
            <g class="atom" id="mol1atm7">
                        
                <path d="M9.385 3.078q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM5.521 3.078q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M4.305 5.531h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm10">
                        
                <path d="M30.876 62.222h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.739h-.565v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M26.433 62.222h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M87.27 18.686q-.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.245 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM83.406 18.686q.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm14" stroke="none"/>
                  
            <g class="atom" id="mol1atm15">
                        
                <path d="M100.44 41.562q-.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.757 .0 -1.263 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.309q.25 -.566 .756 -.882q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .876q.256 .565 .256 1.327zM96.576 41.562q.0 .923 .387 1.459q.393 .529 1.221 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M104.746 44.015h-.619v-2.286h-2.512v2.286h-.614v-4.9h.614v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M73.706 59.222h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M78.012 59.222h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M80.517 60.712h-1.943v-.3l.771 -.779q.222 -.221 .372 -.393q.154 -.175 .232 -.339q.079 -.168 .079 -.364q-.0 -.243 -.147 -.368q-.143 -.129 -.371 -.129q-.215 .0 -.379 .075q-.161 .075 -.328 .207l-.193 -.243q.171 -.146 .393 -.246q.225 -.1 .507 -.1q.411 -.0 .65 .207q.239 .207 .239 .575q.0 .229 -.096 .432q-.093 .2 -.265 .397q-.167 .196 -.392 .418l-.615 .603v.018h1.486v.329z" fill="#3050F8" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd7" stroke="#FF0D0D" x1="8.364" x2="10.098500000000001" y1="6.897" y2="12.2365"/>
            <line class="hi" id="mol1bnd7" stroke="#FF0D0D" x1="8.364" x2="10.098500000000001" y1="6.897" y2="12.2365"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="32.246" x2="38.025999999999996" y1="59.07" y2="57.8445"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="32.246" x2="38.025999999999996" y1="59.07" y2="57.8445"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="26.808" x2="24.037" y1="56.112" y2="51.3445"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="26.808" x2="24.037" y1="56.112" y2="51.3445"/>
            <line class="hi" id="mol1bnd16" stroke="#FF0D0D" x1="94.899" x2="89.94550000000001" y1="39.665" y2="36.797"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="71.77" x2="71.777" y1="52.923" y2="47.228"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"5-HTP has shown some usefulness in some conditions characterized, in part, by serotonin deficits, principally depression. It has also been shown to be useful in some with obesity, insomnia, fibromyalgia and chronic tension headache.","Title":"Oxitriptan","UNII":"9181P3OI6N","Wikidata":"Q27103541","Wikipedia":"5-Hydroxytryptophan","XLogP":-1.2}